RxDoctor Payments Data

Sibel Gullo, MD

Internal Medicine · Nicholasville, KYNPI 1154356731

Payments from drug & device makers

$6,945in general payments, 2019–2025

Across 438 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$724
  • AstraZeneca$669
  • Pfizer$596
  • Amgen$438
  • Novo Nordisk$435
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,945 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,947
Medicare patients
165
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$48,174
JardianceEmpagliflozin30$33,273
JanuviaSitagliptin Phosphate25$28,517
OzempicSemaglutide22$26,617
MounjaroTirzepatide25$26,024
JanumetSitagliptin Phos/Metformin Hcl23$18,341
LinzessLinaclotide24$14,692
RybelsusSemaglutide14$12,522
FarxigaDapagliflozin Propanediol19$11,294
VascepaIcosapent Ethyl19$7,999
Repatha SureclickEvolocumab12$6,606
Epinephrine11$1,935
Levothyroxine Sodium165$1,918
Pantoprazole Sodium111$1,686
Atorvastatin Calcium166$1,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$596$49,35756 claims
MerckJanuvia, Janumet$428$46,85848 claims
Novo NordiskOzempic, Rybelsus$435$39,13936 claims
Boehringer IngelheimJardiance$340$33,27330 claims
Lilly USA, LLCMounjaro$1,084$26,02425 claims
AbbVieLinzess, Synthroid$724$15,53057 claims
AstraZenecaFarxiga$669$11,29419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Nicholasville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →